DDT exposure in early childhood and female breast cancer: Evidence from an ecological study in Taiwan

Background: Socio-economic position is associated with cancer incidence, but the direction and magnitude of this relationship differs across cancer types, geographical regions, and socio-economic parameters. In this nationwide cohort study, we evaluated the association between different individual-level socio-economic and -demographic factors, cancer incidence, and stage at diagnosis in Belgium. Methods: The 2001 census was linked to the nationwide Belgian Cancer Registry for cancer diagnoses between 2004 and 2013. Socio-economic parameters included education level, household composition, and housing conditions. Incidence rate ratios were assessed through Poisson regression models. Stage-specific analyses were conducted through logistic regression models. Results: Deprived groups showed higher risks for lung cancer and head and neck cancers, whereas an inverse relation was observed for malignant melanoma and female breast cancer. Typically, associations were more pronounced in men than in women. A lower socio-economic position was associated with reduced chances of being diagnosed with known or early stage at diagnosis; the strongest disparities were found for male lung cancer and female breast cancer. Conclusions: This study identified population groups at increased risk of cancer and unknown or advanced stage at diagnosis in Belgium. Further investigation is needed to build a comprehensive picture of socio-economic inequality in cancer incidence.

Download Full-text

Age-Specific Spatio-Temporal Patterns of Female Breast Cancer Mortality in Spain (1975–2005)

Annals of Epidemiology ◽

10.1016/j.annepidem.2010.07.102 ◽

2010 ◽

Vol 20 (12) ◽

pp. 906-916 ◽

Cited By ~ 15

Author(s):

María D. Ugarte ◽

Tomás Goicoa ◽

Jaione Etxeberria ◽

Ana F. Militino ◽

Marina Pollán

Keyword(s):

Breast Cancer ◽

Cancer Mortality ◽

Breast Cancer Mortality ◽

Temporal Patterns ◽

Female Breast Cancer ◽

Female Breast ◽

Spatio Temporal

Download Full-text

Study of Gene Expression of Programmed Cell Death Ligand 1 (PD-L1) in Breast Cancer Patients

Tumori Journal ◽

10.1177/03008916211012320 ◽

2021 ◽

Vol 107 (1_suppl) ◽

pp. 2-2

Author(s):

H Gadelrab ◽

M Mokhtar ◽

H Morsy ◽

M Elnaggar

Keyword(s):

Breast Cancer ◽

Cell Death ◽

Programmed Cell Death ◽

Cancer Patients ◽

Therapeutic Response ◽

Female Breast Cancer ◽

Clinicopathological Parameters ◽

Breast Cancer Patients ◽

Expression Levels ◽

Female Breast

Introduction: Breast cancer is the most frequently occurring cancer among females and the second most common cancer overall. Programmed Cell Death Ligand 1 (PD-L1) plays an important role in blocking ‘cancer-immunity cycle’ and is considered as a major inhibitory pathway. The aim of the present study was to clarify the alterations of expression of PD-L1 in peripheral blood mononuclear cytes (PBMCs) of female breast cancer patients and analyze its association with clinico-pathological criteria as well as therapeutic response. Materials and Methods: The study was conducted on 45 female breast cancer patients and 45 female controls. Blood samples were collected followed by PBMCs isolation, total RNA extraction, reverse transcription and finally, quantitative polymerase chain reaction (qPCR) using SYBR Green DNA binding dye. Expression levels of PD-L1 were calculated and then compared with clinicopathological parameters of the patients in addition to initial therapeutic response. Results: A significant difference was detected for PD-L1 expression levels in breast cancer patients compared to controls. A significant association with age, metastatic breast cancer, estrogen receptor (ER) negative status as well as high concentrations of cancer antigen 15-3 (CA15-3) was detected. On the other hand, no significant association was recognized with tumor size, lymph nodal status, histopathological type, grade, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER-2) status, triple negative, among de novo and recurrent metastatic patients and for the number of metastatic sites as well as the therapeutic response. Conclusions: This study paves the way of the use of PD-L1 as a noninvasive prognostic and diagnostic biomarker for poor prognosis of breast cancer.

Download Full-text